Sanofi's Frexalimab Phase 2 Data Shows 41% Reduction In Key Biomarker Of Nerve Cell Damage In Relapsing MS; High-Dose Arm Demonstrates Significant Drop In Plasma Neurofilament Light Chain Levels After 48 Weeks; Supports Potential As High-Efficacy,...
Sanofi's Frexalimab Phase 2 Data Shows 41% Reduction In Key Biomarker Of Nerve Cell Damage In Relapsing MS; High-Dose Arm Demonstrates Significant Drop In Plasma Neurofilament Light Chain Levels After 48 Weeks; Supports Potential As High-Efficacy,...
赛诺菲安万特的Frexalimab第2期数据显示，复发性多发性硬化神经细胞损伤关键生物标志物减少41％；高剂量组48周后血浆神经丝轻链水平显著下降；支持其高功效的可能性，这是一种可自主使用、高效、很可能是一种全新的免疫类药物。
Sanofi's Frexalimab Phase 2 Data Shows 41% Reduction In Key Biomarker Of Nerve Cell Damage In Relapsing MS; High-Dose Arm Demonstrates Significant Drop In Plasma Neurofilament Light Chain Levels After 48 Weeks; Supports Potential As High-Efficacy, Disease-Modifying Treatment; Phase 3 Studies Underway
赛诺菲安万特的Frexalimab二期数据显示，复发性多发性硬化症神经细胞损伤关键生物标志物下降41％；高剂量组在48周后血浆神经丝轻链水平显著下降；支持作为高效治疗、疾病修饰治疗的潜力药物；三期研究正在进行。
Frexalimab new phase 2 data showed reduction of key biomarker of nerve cell damage in relapsing MS
Frexalimab新的二期数据显示，复发性多发性硬化症神经细胞损伤关键生物标志物下降。
- Frexalimab high-dose arm observed a 41% reduction in plasma neurofilament light chain (NfL) levels, a biomarker of nerve cell damage, after 48 weeks of treatment
- Data support potential as a first-in-class, high-efficacy, and disease-modifying treatment for people with relapsing MS
- Phase 3 studies of frexalimab in relapsing MS and non-relapsing secondary progressive MS (nrSPMS) are underway
- Frexalimab高剂量组观察到神经细胞损伤生物标志物——血浆神经丝轻链（NfL）水平下降41％，治疗48周后；
- 数据支持作为首个高效、疾病修饰性治疗复发性多发性硬化症的治疗方法。
- Frexalimab 在复发性多发性硬化症和非复发性二级进行性多发性硬化症（nrSPMS）的三期研究正在进行中。